Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving Immunotherapy
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY, cilt.6, sa.1, ss.59-63, 2022 (ESCI, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 6 Sayı: 1
- Basım Tarihi: 2022
- Doi Numarası: 10.14744/ejmo.2022.78280
- Dergi Adı: EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.59-63
- Anahtar Kelimeler: Hyperprogressive disease, immun checkpoint inhibitors, immunotherapy, PILE score
- Hacettepe Üniversitesi Adresli: Evet
Özet
Objectives: Although immune checkpoint inhibitors (ICIs) became a vital part of cancer care, many patients do not respond to treatment. In this group, a few of the patients with a hyperprogressive disease (HPD) have shorter overall survival (OS) compared with those having a progressive disease (PD). Therefore, biomarkers are needed to differentiate HPD and PD.